Effect of bisphosphonates on periprosthetic bone loss after total knee arthroplasty: a meta-analysis of randomized controlled trials

Mingmin Shi, Lei Chen, Haobo Wu, Yangxin Wang, Wei Wang, Yujie Zhang and Shigui Yan

Abstract

Background: Aseptic loosening and osteolysis are the most common indications after TKA for revision surgery. This meta-analysis which included high-quality randomized controlled trials (RCTs) aimed to analyze the effect of bisphosphonates (BPs) on maintaining periprosthetic bone mineral density (BMD) after total knee arthroplasty.

Methods: PubMed, AMED, EMBASE, the Cochrane library, ISI Web of Science, and China National Knowledge Infrastructure were systematically searched, five RCTs were included and the total number of participants was 188. The weighted mean differences with 95% confidence interval were calculated to evaluate the efficacy of BPs on total BMD of knee and the BMD of different periprosthetic regions. A descriptive review was performed for BP-related adverse effects.

Results: The BPs group presented significantly higher total BMD in proximal part of the tibia than the control group at 3 and 6 months ($P < 0.05$), but no significant difference at 12 months ($P = 0.09$). The BPs group presented significantly higher BMD in the distal aspect of the femur than that in the control group at 3, 6, 12 months. The BPs group presented significantly higher periprosthetic BMD than that in the control group at 3, 6 and 12 months in tibial medial and lateral metaphyseal region, and femoral anterior, central and posterior metaphyseal region ($P < 0.05$), but no significant difference for tibial diaphyseal region at 3, 6, and 12 months. None of the included studies described severe or fatal adverse effects related to BPs.

Conclusion: BPs have a short-term effect on reducing periprosthetic bone loss after total knee arthroplasty. Compared with diaphyseal region, BPs are more effective on the preservation of BMD in medial lateral metaphyseal regions of proximal tibia and in anterior, central, and posterior metaphyseal region of distal femur.

Keywords: Bisphosphonates, Total knee arthroplasty, Bone mineral density, Meta-analysis randomized controlled trial
are inhibitors of bone resorption which promote bone mineralization and inhibit farnesyl pyrophosphate synthase [12, 13]. Some studies revealed that bisphosphonates can decrease fracture risk and prolong survival time of implant [14, 15], and some randomized controlled trials have investigated the effect of reduce periprosthetic bone loss after total knee arthroplasty [16–20]. To confirm the effect of BPs on periprosthetic bone loss after total joint arthroplasty, we have made a previous meta-analysis [21], of which included 14 RCTs in 2012, and the result revealed that BPs could prevent bone loss after arthroplasty in medium-term follow-up. However, there were only 2 RCTs about TKA. Due to increased trend in recent investigations on effect of BPs on periprosthetic bone loss after TKA with large-scale and high quality, it is essential to update the analysis.

This meta-analysis of five high-quality RCTs aimed to analyze the effect of bisphosphonates on periprosthetic bone loss after TKA.

**Methods**

**Literature search**

Two independent investigators searched Electronic databases including PubMed, AMED, EMBASE, the Cochrane library, ISI Web of Science, and China National Knowledge Infrastructure from the inception dates to October 31, 2017. The search used the following keywords: (alendronate OR pamidronate OR etidronate OR zoledronate OR clodronate OR bisphosphonate) AND (arthroplasty OR knee arthroplasty OR joint prosthesis OR joint replacement OR knee replacement). To include additional eligible studies, citation lists of all the selected publications were searched by hand.

**Selection criteria**

The inclusion criteria were as follows: (1) the participants underwent total knee arthroplasty, (2) the intervention was administration of bisphosphonates after total knee arthroplasty, (3) the measurements must include periprosthetic BMD, and (4) the trial design was randomized and controlled. The exclusion criteria were as follows: (1) the participants had any history of bone metabolic diseases, (2) BMD data were not available, (3) the same participants reported in a short follow-up study duplicately.

**Data extraction and outcome measures**

For each initially screened trial, two independent investigators collected the information including name of first author, publication year, sample size, intervention, study duration, co-factors, measurements and loss-to-followup rate. If information was not described as text in the publications, we extracted it from the figures, tables, or other supplementary material. The characteristics of five finally included RCTs [16–20] were showed in Table 1. The primary outcome measurement was total periprosthetic BMD of knee. And the secondary measurement was the BMD of different periprosthetic regions of interest (ROIs), including the tibial regions and the femoral regions (Fig. 1). The tibial regions including medial metaphyseal region (R1), lateral metaphyseal region (R2), and diaphyseal region (R3). The femoral regions including anterior metaphyseal region (R4), central metaphyseal region (R5), and posterior region (R6). Because BMD levels are affected by gender, weight and general bone loss, the results were presented as a percentage of the BMD changing from the baseline. The percentage of BMD changing was used rather than the absolute numerical value to decrease the bias of different baseline. The percentage of BMD changing was calculated as follows: 100*(BMDières-BMD0)/BMD0. Here BMDères refers to the baseline BMD value, and BMDn stands for the post-operative BMD at certain follow-up time point. Sensitivity analysis was performed for the effect size by omitting the studies for which data were imputed.

**Table 1** Characteristics of the included studies

| Study       | Age (years), I/C | Sample Size, I/C | Intervention                                                                 | Follow-up (month) | Outcome Measures                              |
|-------------|------------------|------------------|------------------------------------------------------------------------------|-------------------|-----------------------------------------------|
| Solinvaara  | 83.5 ± 19.9/ 79.7 ± 8.7 19 (8/11) | 10 mg/day oral alendronate+ 500 mg/day calcium carbonate for 12 months vs. 500 mg/day calcium carbonate | 12 months         | Periprosthetic BMD: proximal femur            |
| Han         | 63.6 ± 4.1/ 65.2 ± 5.6 72 (36/36) | 10 mg/day oral alendronate for 6 months vs. no placebo                     | 12 months         | Periprosthetic BMD: distal part of femur and proximal aspect of tibia |
| Wang        | 69.8 ± 5.9/ 69.7 ± 6.7 60 (30/30) | 10 mg/day oral alendronate for 6 months vs. no placebo                     | 3 years           | Periprosthetic BMD: distal part of femur and proximal aspect of tibia |
| Abu-Rajab   | 68 ± 2.2/ 72 ± 8.1 11 (5/6) | 70 mg/week oral alendronate for 6 months vs. a placebo                    | 2 years           | Periprosthetic BMD: distal part of femur and proximal aspect of tibia |
| Jaroma      | 66 ± 7.0/ 68 ± 8.2 26 (14/12) | 10 mg/day oral alendronate+ 500 mg/day calcium carbonate for 12 months vs. 500 mg/day calcium carbonate | 7 years           | Periprosthetic BMD: distal part of femur and proximal aspect of tibia |

I/C intervention/control groups, BMD bone mineral density
Methodological quality assessment
The methodologic quality of included trials were assessed by two investigators independently with the Cochrane Collaboration tool for risk of bias, in which assessing factors included randomization, allocation concealment, and blinding etc. The weighted kappa for the agreement on the assessment of quality between all reviewers was 0.89 [95% confidence interval (CI), 0.80–0.99]. The criteria of the Grading of Recommendations Assessment, Development and Evaluation (GRADE) were used to assess the quality of evidence [22].

Statistical analysis
For data reported as continuous variables, means and standard deviations were extracted. All extracted data were input and analyzed in Review Manager 5.3.5 version (Cochrane Collaboration, London, England). Chi-square test and $I^2$ was used to assess heterogeneity the [23]. When there was no statistical heterogeneity ($P<0.10$, or $I^2<50\%$), the fixed-effect (FE) model was used; otherwise ($P>0.10$, or $I^2>50\%$), a random-effect (RE) model was chosen [24].

Sensitivity were evaluated by omitting some trials to assess whether specified factors (small sample size, randomization, intention-to-treat (ITT) analysis etc) could affect the overall result of analysis. The $P$ value of heterogeneity less than 0.05 was considered as significant differences. The analyses of sensitive could not be performed when the number of trials was less than three in comparison.

Results
Trials selection
A flow diagram illustrating the study identification is shown in Fig. 2. There were 353 relevant trials selected by initially search, of which 269 trials were excluded because they were duplicated or non-clinical trial. Of the 84 remaining articles, only 10 studies were on the main topic. Among the 10 studies, one trial [25] was excluded because there were longer follow-up and re-analyzed studies reported the same participants. But the data from these shorter-term follow-up trials were considered to be used when they were analyzed in other later trials. Two excluded trials had no available BMD data [26, 27]. Two trials were excluded because they were non-RCTs [14, 28]. Finally, 5 RCTs involving 188 participants were included in our meta-analysis (Fig. 1). The weighted kappa for agreement on eligibility between reviewers was 0.88 (95% CI, 0.80–0.96).

The characteristics of the included trials were summarized in Table 1. The BPs used in all the five trials were alendronate.
demonstrated sufficient allocation concealment, two studies described the blinding of outcome assessment and two studies described the blinding of participants. All the five studies retained complete outcome data, avoided selective reporting, and seemed to be free of other potential sources of bias. The investigators achieved good agreement in evaluating the methodological quality (0.86, 95% CI: 0.82–0.90).

Preservation of total periprosthetic BMD
It was illustrated that the BPs group presented significantly higher total BMD in proximal part of the tibia than the control group at 3 and 6 months respectively [(2 trials, WMD: 3.40, 95% CI: 2.06–4.73, \( p < 0.05 \)); (3 trials, WMD: 2.66, 95% CI: 1.63–3.69, \( p < 0.05 \))] (Fig. 4a and b). There was no significant difference of total BMD in proximal part of the tibia between the BPs group and the control group at 12 months (3 trials, WMD: -1.01, 95% CI: -2.19–0.17, \( p = 0.09 \)) (Fig. 4c). The BPs group presented significantly higher BMD in the distal aspect of the femur than that in the control group at 3, 6, 12 months [(3 trials, WMD: 5.64, 95% CI: 4.42–6.85, \( p < 0.05 \)); (5 trials, WMD: 7.22, 95% CI: 5.88–8.57, \( p < 0.05 \)); (4 trials, WMD: 18.46, 95% CI:17.09–19.83, \( p < 0.05 \))] (Fig. 5).

Preservation of BMD in different knee regions
It was illustrated that the BPs group presented significantly higher periprosthetic BMD than that in the control
group at 3, 6 and 12 months in R1, R2, R4, R5 and R6 ($p < 0.05$) (Table 2). For R3, there was no significant difference of periprosthetic BMD between the BPs group and the control group at 3, 6, and 12 months ($p < 0.05$).

**Heterogeneity and sensitivity analysis**

The BMD in proximal part of the tibia and the distal aspect of the femur at different follow-up were statistically heterogeneous at 6 (tibia: $\chi^2 = 30.26, p < 0.00001, I^2 = 93$%; femur: $\chi^2 = 40.07, p < 0.00001, I^2 = 90$%) and 12 months respectively (tibia: $\chi^2 = 13.81, p < 0.00001, I^2 = 86$%; femur: $\chi^2 = 10.98, p < 0.00001, I^2 = 73$%) but not at 3 months (Fig. 4 and Fig. 5). The heterogeneity could not be minimized by omitting any trial. The overall effect was not significantly altered by omitting trials without the ITT analysis, those with small sample size (less than 20), or those funded by companies.

**Strength of evidence.**

No serious adverse effect was reported related to BPs in the 5 trials. The mostly reported adverse effect was digestive discomfort in 3 trials: 1 of 8 by Soininvaara [16]; 5 patients

| Study or Subgroup | BPs | Control | Mean Difference | Mean Difference |
|-------------------|-----|---------|----------------|----------------|
| Han 2003          | -4.9| 3.45    | 36             | 36             |
| 3                | -9.9| 5.64    | 31.5%          | 5.00 [2.84, 7.16] |
| Jaroma 2015       | -6.16| 2.45   | 12             | 14             |
| 3                | -11.43| 2.07  | 47.4%          | 5.27 [3.51, 7.03] |
| Soininavaara 2002 | -3.4| 2.47    | 8              | 11             |
| 3                | -10.8| 3.39   | 21.1%          | 7.40 [4.77, 10.03] |
| Total (95% CI)    | 56  | 61      | 100.0%         | 5.64 [4.42, 6.85] |

**Table 2 Meta-analyses of BMD of the different regions of knee at different time points**

| ROI | 3 months | 6 months | 12 months |
|-----|----------|----------|-----------|
| WMD (95%CI) | WMD (95%CI) | WMD (95%CI) |
| Tibia | 1.490 (3.53, 6.26) | 6.63 (5.34, 7.93) | 4.22 (2.92, 5.51) |
| 2.61 (1.32, 3.91) | 5.86 (4.57, 7.16) | 8.57 (7.28, 9.87) |
| 1.10 (-0.19, 2.40) | 0.45 (-0.84, 1.75) | 0.36 (0.94, 1.65) |
| P = 0.18 | P = 0.39 | P = 0.44 |
| Femur | 4.10 (2.74, 5.46) | 4.50 (3.13, 5.86) | 5.70 (4.34, 7.06) |
| 6.90 (5.54, 8.27) | 6.50 (5.14, 7.87) | 7.02 (5.66, 8.39) |
| 4.34 (2.97, 5.70) | 4.32 (2.96, 5.68) | 5.25 (3.89, 6.62) |

ROI: region of interest, WMD: weighted mean differences

A positive value of WMD means it favors experimental, and negative value means favoring control.
by Wang [18]; 2 patients by Jaroma [20]. There was no severe side effect on renal, hepatic, or heart function.

Discussion

High BMD supports bone-implant fixation, and there have been several attempts to improve the quality of the primary arthroplasty and to reduce the incidence of failures caused by loss of BMD [29, 30]. A large population-based parallel-cohorts study [31] found that bisphosphonates could decrease the risk of periprosthetic fractures after THA. A larger retrospective cohort study on participants with primary total hip/knee arthroplasty showed that oral bisphosphonates reduced risk of revision surgery by 59% compared with the control group. However, this difference was not found in TKA patients who used BPs, but the numbers were very small [32]. The present meta-analysis strengthened the evidence of BPs reducing periprosthetic bone loss.

Our previous meta-analyses based on 14 RCTs [21] found that BPs significantly preserved total periprosthetic BMD up to 10 years after joint arthroplasty. However, most included trials in that meta-analyses were in regards to THA, and there was only 2 RCTs about the TKA. More significant efficacy in proximal tibia was found at 3 and 6 months after arthroplasty in the BPs group compared with the control group. However, this difference was not significant at 12 months after arthroplasty. The reason that later stages after surgery have respectively lower efficacy may be the active bone resorption caused by the early iatrogenic damage and the late stress shielding induced osteolysis [33]. Meanwhile, more significant efficacy in distal femur was found at 3, 6 and 12 months after arthroplasty in the BPs group compared with the control group. Moreover, the secondary finding is that different femoral region has different response to bisphosphonates. In the proximal tibial region R1 and R2, BPs group presented significantly higher periprosthetic BMD than that control group up to 12 months after arthroplasty, and in the proximal tibial region R3, the BPs group presented significantly higher periprosthetic than that control group up to 12 months after arthroplasty. The possible interpretation is that the medial and lateral metaphyseal region have more stress shielding than diaphyseal region [34]. In the distal femoral region R1, R2 and R3, BPs group presented significantly higher periprosthetic BMD than that control group at 3, 6 and 12 months after surgery. The possible interpretation is that these three regions have similar mechanical environment which provides similar stress shielding [35]. The present study showed there was no serious adverse effect related to BPs. It was reported a higher risk of periprosthetic fractures was found in TKA patients who used BPs, but the number of included patients less than 150 is considered to be small and may cause imprecision [36]. As there was no atypical femur fracture observed in this meta-analysis, there are likely to be a variety of factors involved in peri-prosthetic fracture, such as femoral geometry, prolonged duration of BP use, smoking, and activity level.

The strengths of our meta-analysis include the most included trials and largest sample size investigating the effect of BP treatment following TKA. According to the GRADE system for evidence quality, all the included trials in the present meta-analysis began as high-quality or moderate-quality evidence, which was downgraded by five categories of limitations (Table 3). Inadequate blinding and substantial loss follow-up in some trials might reduce the quality. The number of included patients less than 150 is considered to be small and may cause imprecision and effect size more than 0.05 is considered to be large and strengthen the evidence.

The present meta-analysis has several limitations. Firstly, the limited number of trials and small sample size in some trials might reduce the precision of the pooled estimates. Secondly, the inclusion criteria and baseline characteristics of the included trials were heterogeneous, including the primary diseases, gender, ages of patients and the type of prosthesis, which would lead to bias. Thirdly, trials included in this meta-analysis only used alendronate. Finally, the presented study analyzed the short-term effect of BPs on periprosthetic bone loss after TKA, and

---

**Table 3** GRADE evidence profile of RCTs for effect of BPs on periprosthetic bone loss after TKA

| Summary of findings | Quality assessment |
|---------------------|-------------------|
| Time points | WMD (95%CI, g/cm²) | Limitations | Inconsistency | Indirectness | Imprecision | Others | Quality |
| **Tibia** | | | | | | | |
| 3 months | 2 (48/50) | 0.07 (0.04–0.10) | No serious a | No serious b | No serious c | Serious d | Strong association e Moderate |
| 6 months | 3 (78/80) | 0.12 (0.10–0.15) | No serious | No serious | No serious | No serious | Strong association e High |
| 12 months | 3 (77/75) | 0.12 (0.10–0.15) | No serious | Serious | No serious | No serious | None | Moderate |
| **Femur** | | | | | | | |
| 3 months | 3 (56/61) | 0.07 (0.04–0.10) | No serious | No serious | No serious | No serious | Strong association e Moderate |
| 6 months | 5 (91/97) | 0.12 (0.10–0.15) | No serious | No serious | No serious | No serious | Strong association e Moderate |
| 12 months | 4 (85/86) | 0.12 (0.10–0.15) | No serious | No serious | No serious | No serious | Strong association e Moderate |

---

aThe inadequate blinding and substantial loss follow-up in some trials may raise risk of bias
bInconsistent report of outcomes and significant heterogeneity existed across the trials
cThe number of included patients less than 150 is considered to be small and may cause imprecision
dEffect size more than 0.05 is considered to be large and strengthen the evidence
the long-term effect remained unknown and required more clinical studies.

**Conclusion**

In the present meta-analysis of randomized clinical trials, BPs have a short-term effect on the preservation of peri-prosthetic BMD after total knee arthroplasty. Compared with diaphyseal region, BPs are more effective on the preservation of BMD in medial lateral metaphyseal regions of proximal tibia and in anterior, central, and posterior metaphyseal region of distal femur.

**Abbreviations**

BMD: Bone mineral density; BPs: Bisphosphonates; CI: Confidence interval; FE: Fixed-effect; GRADE: Grading of Recommendations Assessment, Development and Evaluation; ITT: Intention-to-treat; RCTs: Randomized controlled trials; RE: Random-effect; ROIs: Regions of interest; TKA: Total knee arthroplasty; WMD: Weighted mean difference

**Acknowledgements**

The corresponding author wishes to thank all the co-authors for their contributions.

**Funding**

This research was supported by National Natural Science Foundation of China under Grant No. 81772360, Zhejiang Province Natural Science Foundation of China under Grant No. LQ16H060002, Zhejiang Province Natural Science Foundation of China under Grant No. Y17H060027, Medical and Health Science and Technology Project of Zhejiang Province under Grant No. 2016KYB120, Health Foundation of Zhejiang Province under Grant No.2018263059 and China Postdoctoral Science Foundation under Grant No. 2017M612012.

**Availability of data and materials**

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

**Authors’ contributions**

MS and LC searched the databases and performed data extraction and quality assessment; MS, WW and SY designed the study; MS, YW, WW, YZ and SY analyzed the data and wrote the manuscript. All authors read and approved the final content of the manuscript. HW and SY revised the manuscript.

**Ethics approval and consent to participate**

The present article does not contain any studies with human participants or animals performed by any of the authors. There is no need for ethical approval and informed consents.

**Competing interests**

The authors declare that they have no competing interests.

**Publisher’s Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Author details**

1Department of Orthopaedic Surgery, Second Affiliated Hospital, School of Medicine, Zhejiang University, No.88 Jiefang Road, Hangzhou 310009, People’s Republic of China. 2Department of Endocrinology and Metabolism, Sir Run Run Shaw Hospital Affiliated with School of Medicine, Zhejiang University, No. 3 Qingchun Road, Hangzhou 310009, People’s Republic of China.

**Received: 28 January 2018 Accepted: 17 May 2018 Published online: 30 May 2018**

**References**

1. Huang CC, Jiang GC, Hsieh CH, Tsai CJ, Chang H. Local bone quality affects the outcome of prosthetic total knee arthroplasty. J Orthop Res. 2016;34(2):240–4.
2. Winther N, Jensen C, Petersen M, Lind T, Schröder H, Petersen M. Changes in bone mineral density of the proximal tibia after un cemented total knee arthroplasty. A prospective randomized study. Int Orthop. 2016;40(2):285–94.
3. van Loon CJ, Oyen WJ, de Waal Malefijt MC, Verdonschot N. Distal femoral bone mineral density after total knee arthroplasty: a comparison with general bone mineral density. Arch Orthop Trauma Surg. 2001;121(5):282–5.
4. Sundfeldt M, Carlsson LV, Johansson CB, Thomsen P, Greitzer C. Aseptic loosening, not only a question of wear: a review of different theories. Acta Orthop. 2006;77(2):177–97.
5. Munro JT, Pandit S, Walker CG, Clatworthy M, Pitt R. Loss of tibial bone density in patients with rotating- or fixed-platform TKA. Clin Orthop Relat Res. 2010;468(3):775–81.
6. Järvenpää J, Soninvaara T, Kettunen J, Miettinen H, Körger H. Changes in bone mineral density of the distal femur after total knee arthroplasty: a 7-year DEKA follow-up comparing results between obese and nonobese patients. Knee. 2014;21(1):232–5.
7. Spinarelli A, Pettera M, Vicenti G, Pesce V, Patella V. Total knee arthroplasty in elderly osteoporotic patients. Aging Clin Exp Res. 2011;23(2 Suppl):78–80.
8. Petersen MM, Lauritzen JB, Pedersen JG, Lund B. Decreased bone density of the distal femur after un cemented knee arthroplasty: A 1-year follow-up of 29 knees. Acta Orthop Scand. 1996;67(4):339–44.
9. Seki T, Omori G, Koga Y, Suzuki Y, Ishii Y, Takahashi HE. Is bone density in the distal femur affected by use of cement and by femoral component design in total knee arthroplasty? J Orthop Sci. 1999;4(3):180–6.
10. Soninvaara TA, Miettinen HJ, Jurvelin JS, Miettinen H, Alhava EM, Körger HP. Periprosthetic femoral bone loss after total knee arthroplasty: 1-year follow-up study of 69 patients. Knee. 2004;11(4):297–302.
11. Cherian JJ, Jauregui JJ, Banerjee S, Pierce T, Mont MA. What host factors affect aseptic loosening after THA and TKA? Clin Orthop Relat Res. 2015;473(8):2700–9.
12. Cranney A, Wells G, Willan A, Griffith L, Zytaruk N, Robinson V, et al. Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women. Endocr Rev. 2002;23(4):508–16.
13. Catterall JB, Cawston TE. Drugs in development: bisphosphonates and metalloproteinase inhibitors. Arthritis Res Ther. 2003;5(S1):121–24.
14. Fu SH, Wang CY, Yang RS, Wu FL, Hisao FY. Bisphosphonate use and the risk of undergoing Total knee arthroplasty in osteoporotic patients with osteoarthritis: a Nationwide cohort study in Taiwan. J Bone Joint Surg Am. 2017;99(11):938–46.
15. Khatoor M, Inacio MC, Dell RM, Bini SA, Paxton EW, Namba RS. Association of Bisphosphonate use and Risk of revision after THA: outcomes from a US Total joint replacement registry. Clin Orthop Relat Res. 2015;473(11):3412–20.
16. Soninvaara TA, Jurvelin JS, Miettinen HJ, Suomalainen DT, Alhava EM, Körger PJ. Effect of alendronate on peri-prosthetic bone loss after total knee arthroplasty: a one-year, randomized, controlled trial of 19 patients. Calcif Tissue Int. 2002;71(6):472–7.
17. Han H, Li X, Wang Y, Zeng X, Preventing XC. Prosthesis loss in joint replacement. Chinese journal of surgery of integrated traditional and western. Medicine. 2003;9(3):179–82.
18. Wang CJ, Wang JW, Ko JY, Weng LH, Huang CC. Three-year changes in bone mineral density around the knee after a six-month course of oral alendronate following total knee arthroplasty. A prospective, randomized study. J Bone Joint Surg Am. 2006;88(2):267–72.
19. Abu-Rajab RB, Watson W, Gallacher P, Walker B, Meek RMD. The effect of 6 months oral alendronate treatment on periprosthetic bone loss after total knee arthroplasty: a one-year, randomized, controlled trial of 26 patients. Bone Joint J. 2015;97-B(3):337–45.
20. Iaroma AV, Soninvaara TA, Körger H. Effect of one-year post-operative alendronate treatment on peri-prosthetic bone after total knee arthroplasty. A seven-year randomised controlled trial of 26 patients. Bone Joint J. 2015;97-B(3):337–45.
21. Lin T, Yan SG, Cai XZ, Ying ZM. Bisphosphonates for periprosthetic bone loss after joint arthroplasty: a meta-analysis of 14 randomized controlled trials. Osteoporos Int. 2012;23(6):1823–34.
22. Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S, et al. Grading quality of evidence and strength of recommendations. BMJ. 2004;328(7454):1490.
23. JPT H, Green S. Cochrane handbook for systematic reviews of interventions. Chichester, England: Wiley-Blackwell; 2008.
24. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557–60.
25. Wang CJ, Wang JW, Weng LH, Hsu CC, Huang CC, Chen HS. The effect of alendronate on bone mineral density in the distal part of the femur and proximal part of the tibia after total knee arthroplasty. J Bone Joint Surg Am. 2003;85-A(11):2121–6.
26. Lee JK, Lee CH, Choi CH. QCT bone mineral density responses to 1 year of oral bisphosphonate therapy after total knee replacement for knee osteoarthritis. Osteoporos Int. 2013;24(1):287–92.
27. Hanson U, Tolksvig-Larsen S, Ryd L, Aspénberg P. Once-weekly oral medication with alendronate does not prevent migration of knee prostheses: a double-blind randomized RSA study. Acta Orthop. 2009;80(1):41–5.
28. Prieto-Alhambra D, Javid MK, Judge A, Murray D, Carr A, Cooper C, et al. Association between bisphosphonate use and implant survival after primary total arthroplasty of the knee or hip: population based retrospective cohort study. BMJ. 2011;343:d7222.
29. Jansen JP, Bergman GJ, Huels J, Olson M. The efficacy of bisphosphonates in the prevention of vertebral, hip, and nonvertebral-nonhip fractures in osteoporosis: a network meta-analysis. Semin Arthritis Rheum. 2011;40(4):275–84, e1–2.
30. Ji WP, Wang XL, Ma MQ, Lan J, Li H. Prevention of early bone loss around the prosthesis by administration of anti-osteoporotic agents and influences of collared and non-collared femoral stem prostheses on early periprosthetic bone loss. Eur J Orthop Surg Traumatol. 2013;23(5):565–71.
31. Prieto-Alhambra D, Javid MK, Judge A, Maskell J, Kiran A, de Vries F, et al. Fracture risk before and after total hip replacement in patients with osteoarthritis: potential benefits of bisphosphonate use. Arthritis Rheum. 2011;63(4):992–1001.
32. Prieto-Alhambra D, Lalmohamed A, Abrahamsen B, Arden NK, de Boer A, Vestergaard P, et al. Oral bisphosphonate use and total knee/hip implant survival: validation of results in an external population-based cohort. Arthritis Rheumatol. 2014;66(11):3233–40.
33. Lee JK, Choi CH, Kang CN. Quantitative computed tomography assessment of bone mineral density after 2 years’ oral bisphosphonate treatment in postmenopausal osteoarthritis patients who underwent total knee arthroplasty. J Int Med Res. 2013;41(3):878–88.
34. Jaroma A, Soiniavara T, Kröger H. Periprosthetic tibial bone mineral density changes after total knee arthroplasty. Acta Orthop. 2016;87(3):268–73.
35. Srinivasan P, Miller MA, Verdonschot N, Mann KA, Jansen D. Experimental and computational micromechanics at the tibial cement-trabeculae interface. J Biomech. 2016;49(9):1641–8.
36. Namba RS, Inacio MC, Cheetham TC, Dell RM, Paxton EW, Khatod MX. Lower Total knee arthroplasty revision risk associated with bisphosphonate use, even in patients with normal bone density. J Arthroplast. 2016;31(2):S37–41.